HLN
NYSE
$10.05
Haleon plc (HLN)
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
Sector:
Healthcare
Buy
Target: $11.65 (+15.98%)
Market Cap
$44B
PEG Ratio
0.26
P/E Ratio
12.02
Free Cash Flow Yield
14.19%
Price Chart
Valuation
Market Cap$44B
P/E12.02
Forward P/E19.12
PEG0.26
P/S3.89
P/B1.97
Profitability
Total Revenue (TTM)$26B
Gross Profit (TTM)$9.63B
EBITDA$6.41B
Profit Margin15.5%
Operating Margin22.7%
EPS$0.81
Financial Health
Debt-to-Equity52.4%
Free Cash Flow Yield14.19%
Dividend Yield1.91%
Growth & Risk
Beta (5Y)0.13
Sharpe Ratio0.24